One-stage and two-stage designs for phase II clinical trials with survival endpoints

Statistics in Medicine

Volumn 33, Issue 22, 2014, Pages 3830-3843

  Whitehead, John ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Cancer trial; Phase II trial; Sample size calculation; Survival data; Two stage designs

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOASSAY; CHEMORADIOTHERAPY; COMPUTER SIMULATION; HUMAN; METHODOLOGY; PANCREATIC NEOPLASMS; PHASE 2 CLINICAL TRIAL (TOPIC); STATISTICAL MODEL; SURVIVAL ANALYSIS;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; ENDPOINT DETERMINATION; HUMANS; MODELS, STATISTICAL; PANCREATIC NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 84906822793     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6196     Document Type: Article

References (21)

1. Stallard N. Phase II clinical trials. In Statistical Advances in the Biomedical Sciences, Biswas A, Datta S, Fine M, Segal MR (eds). Wiley-Interscience: Hoboken, N. J., 2008; 15-32.
2. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 1989; 10: 1-10.
3. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine 1997; 16: 2701-2711.
4. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
5. Bellisant E, Benichou J, Chastang C. Application of the triangular test to phase II cancer clinical trials. Statistics in Medicine 1990; 9: 907-917.
6. Lin SP, Chen TT. Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses. Communications in Statistics - Theory and Methods 2000; 29: 923-940.
7. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. Journal of Chronic Diseases 1961; 13: 346-353.
8. Case LD, Morgan TM. Design of phase II cancer trials evaluating survival probabilities. BMC Medical Research Methodology 2003; 3: 6.
9. Owzar K, Jung SH. Designing phase II studies in cancer with time-to-event endpoints. Clinical Trials 2008; 5: 209-221.
10. Sun X, Peng P, Tu D. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion. Contemporary Clinical Trials 2011; 32: 108-113.
11. Woolson RF. Rank tests and a one-sample log rank test for comparing observed survival data to a standard population. Biometrics 1981; 37: 687-696.
12. Thall PF, Wooten LH, Tanir NM. Monitoring event times in early phase clinical trials: some practical issues. Clinical Trials 2005; 2: 467-478.
13. Zhao L, Taylor JMG, Schuetze SM. Bayesian decision theoretic two-stage design in phase II clinical trials with survival endpoint. Statistics in Medicine 2012; 31: 1804-1820.
14. Whitehead J. The Design and Analysis of Sequential Clinical Trials, (revised second edition). Wiley: Chichester, 1997.
15. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404-413.
16. Jovic G, Whitehead J. An exact method for analysis following a two-stage phase II cancer clinical trial. Statistics in Medicine 2010; 29: 3118-3125.
17. Lin DY, Shen L, Ying Z, Breslow NE. Group sequential designs for monitoring survival probabilities. Biometrics 1996; 52: 1033-1042.
18. Whitehead J. Group sequential trials revisited: simple implementation using SAS. Statistical Methods in Medical Research 2011; 20: 636-656.
19. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, Le Blanc M, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research 2010; 16: 1764-1769.
20. Whitehead J, Valdés-Márquez E, Johnson P, Graham G. Bayesian sample size for exploratory clinical trials incorporating historical data. Statistics in Medicine 2008; 27: 2307-2327.
21. Cotterill A, Whitehead J. A Bayesian method for setting sample sizes and choosing allocation ratios in phase II clinical trials with exponential and Weibull distributed time-to-event endpoints. In preparation.